This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Galantamine
Plant alkaloid from the snowdrop (Galanthus nivalis) with a dual mechanism that none of this user's other cholinergics share — reversible AChE…
Aliases (7)
Overview
What is Galantamine?
Galantamine (Razadyne) is an alkaloid from Galanthus (snowdrop) and Lycoris bulbs, FDA-approved as an acetylcholinesterase inhibitor for mild-to-moderate Alzheimer's disease. Also used by lucid-dreaming community.
Key Benefits
Modest cognitive support in Alzheimer's, may improve memory and attention, popular in the lucid-dreaming community for vivid REM sleep when timed with WBTB protocols. Some healthy-adult use for memory consolidation.
Mechanism of Action
Reversibly inhibits acetylcholinesterase to raise synaptic acetylcholine, plus allosterically potentiates nicotinic acetylcholine receptors (alpha-7 and alpha-4-beta-2). The dual mechanism is unique among the AChEi class.
Pharmacokinetics
▸Brand options7 known
StatusUS — Rx only (FDA-approved 2001 for mild-moderate Alzheimer's; no DEA schedule, not controlled). EU/UK — Rx only. Bulgaria — original Nivalin Rx. **Trace doses appear OTC in some "lucid dreaming" sleep stacks** (4-8 mg galantamine HBr; legality borderline — sold as supplement under DSHEA in US but technically a drug).
Research Indications
Anti-inflammatory via the cholinergic anti-inflammatory pathway (vagal α7-mediated)
α7 stimulation on macrophages reduces TNF-α release. This is the basis for some sepsis / colitis preclinical work (Tracey lab) and the br…
Possible neuroprotection via α7 nAChR
α7 activation has been shown to reduce amyloid-β toxicity in vitro and in transgenic mouse models (Wang 2003, Liu 2020). Underpins the in…
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
(the user's V stack): ✅ The Kennedy-pathway choline + cytidine substrate provides what galantamine's APL action sensitizes the receptors to. Mechanistically …
(PRN): ✅ Stronger acute choline elevation than citicoline; the lucid-dream community stacks alpha-GPC 300-600 mg with galantamine 4-8 mg WBTB. Best pairing f…
(V5 plan): ✅ Acetyl group substrate for ChAT; potentiates the cholinergic loading. Mechanism-additive.
(V5 plan): ⚠️ Modafinil increases ACh demand cortically; galantamine extends ACh tone. Theoretically synergistic for sustained cognitive performance, but the…
❌ Additive AChE inhibition → cholinergic excess (severe nausea, bradycardia, sweating, possibly cholinergic crisis). Standard contraindication.
(oxybutynin, tricyclic antidepressants like amitriptyline, first-gen antihistamines like diphenhydramine, scopolamine): ❌ Mechanism-opposing. Galantamine's e…
(depolarizing neuromuscular blocker used in surgery): ❌ Galantamine-like AChEIs prolong succinylcholine action via butyrylcholinesterase inhibition. Surgical…
(beta-blockers, non-DHP calcium channel blockers, digoxin, amiodarone): ⚠️ Additive bradycardia / heart-block risk. Relevant if the user ever goes on propran…
(chronic, high dose): ⚠️ Galantamine increases gastric acid secretion via vagal stimulation; concurrent chronic NSAID use mildly elevates GI bleeding risk.
❌ At a chronic level (citicoline + alpha-GPC + galantamine), cholinergic over-tone is a real risk → flat affect, GI symptoms, bradycardia, sleep disruption. …
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Onset30-60 min; peak 1-2 hr.
- Onset1-2 hr; peak 2-4 hr.
- Acute"feel" dampens within 1-2 weeks of titration. Therapeutic effect is slowing of cognitive decline, not subjective enhancement.
Side Effects & Safety 13
Side Effects
- 1Nausea (24-37% in AD trials at full dose; 5-15% at 4-8 mg PRN with food)
- 2Vomiting (13-20% at full dose during titration)
- 3Diarrhea (9-12%)
- 4Anorexia / weight loss (7-9% at full dose; meaningful — average 2-3 kg over 6 months in AD trials)
- 5Headache (5-8%)
- 6Dizziness (8-9%)
- 7Vivid dreams / nightmares (5-10% — cholinergic REM activation; this is the lucid-dream mechanism but also a side effect for non-target users)
- 8Insomnia / sleep disruption — bimodal: some users get vivid dreams that improve sleep quality; others get fragmented REM.
- 9Bradycardia — 1-3% at therapeutic doses. Cholinergic vagal tone → slowed heart rate. Relevant for users in this archetype as an athlete with already-low resting HR (likely 50-60 bpm); galantamine could push toward symptomatic bradycardia.
- 10Hypotension, syncope — rare but documented; cholinergic-mediated.
- 11Urinary frequency, incontinence — peripheral cholinergic.
- 12Tremor, muscle cramps — peripheral nAChR activation at NMJ.
- 13Depression / mood changes — chronic cholinergic over-tone; mostly seen at chronic 24 mg/day.
When to Stop
- Severe bradycardia / heart block — particularly in patients with conduction abnormalities. All AChEIs carry this risk; galantamine is not unique. Rare in healthy young adults.
- Stevens-Johnson syndrome / TEN — exceedingly rare; case reports only. Not a major class concern (unlike modafinil's well-documented SJS signal).
- Seizures — AChEIs can lower seizure threshold; rare in absence of seizure history.
- Asthma / COPD exacerbation — cholinergic bronchoconstriction; relative contraindication in severe pulmonary disease.
- GI bleeding — modest increased risk via cholinergic GI hypersecretion + NSAID interaction.
- Galantamine-MCI mortality signal: Two pooled MCI trials (Gal-Int-11, Gal-Int-18) showed 1.4% all-cause mortality in galantamine arms vs 0.3% in placebo over 24 months. Cause unclear; possibly chance, possibly genuine harm in non-target population. FDA labeled this in 2005. Important caution flag for off-label use in non-AD populations — the mechanism by which a beneficial drug in AD might be harmful in MCI is not understood.
- First 2-4 weeks of any chronic use: GI tolerance + cardiovascular monitoring (HR, BP).
- Titration windows in chronic AD use: dose increases at 4-week intervals; each titration step is when adverse events spike.
- Lucid-dreaming PRN use: acute risk window is the night of dosing — nausea, sleep fragmentation, vivid nightmares possible. Generally clears by morning.
References
Loy & Schneider Cochrane review — Galantamine for Alzheimer's disease and mild cognitive impairment
keystone systematic review confirming cognitive + ADL benefit in mild-moderate AD.
View StudyLaBerge S, LaMarca K, Baird B 2018 — Pre-sleep treatment with galantamine stimulates lucid dreaming: A double-blind, placebo-controlled, crossover study (PLOS ONE)
keystone lucid-dream RCT, n=121, 4 mg + 8 mg dose-dependent effect with WBTB.
View StudyTariot PN et al. 2000 — A 5-month, randomized, placebo-controlled trial of galantamine in AD (Neurology)
phase III FDA approval trial.
View StudyWilcock GK et al. 2000 — Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease (BMJ)
phase III trial.
View StudyRaskind MA et al. 2000 — Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension (Neurology)
phase III trial + extension.
View StudyErkinjuntti T et al. 2002, Lancet — Efficacy of galantamine in probable vascular dementia and AD with cerebrovascular disease
VaD/mixed dementia evidence base.
View StudyMaelicke A et al. 2001, Biol Psychiatry — Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease
keystone α7 nAChR APL mechanism paper.
View StudySamochocki M et al. 2003, J Pharmacol Exp Ther — Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors
APL mechanism characterization.
View StudyFDA Razadyne (galantamine) label
official prescribing information including MCI mortality warning.
View StudyMota-Rolim SA et al. 2013, Front Psychol — Neurobiology and clinical implications of lucid dreaming
earlier lucid-dream work, supports LaBerge.
View StudyWang HY et al. 2003, J Neurosci — α7 nAChR-amyloid β interaction in Alzheimer's pathology
α7 mechanism in AD.
View StudyFreedman R et al. 2007, Schizophr Bull — α7 nicotinic receptor agonists for cognitive enhancement in schizophrenia
α7 hypothesis in schizophrenia.
View StudyDrugBank — Galantamine
pharmacokinetics, CYP metabolism, interactions reference.
View StudyPsychonautWiki — Galantamine
community subjective effects + lucid-dream protocol synthesis.
View Studyr/LucidDreaming galantamine megathread
community protocol and side-effect anecdata.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.